

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Box Petition, P. O. Box 1450, Alexandria, VA 22313-1450 on this 1st day of November, 2004.



By

Kelly A. Smith

(Signature of person mailing)
Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ghazwan Saleem Butrous :

APPLICATION NO.: 09/692,807 : Examiner: Dwayne C. Jones

FILING DATE: October 20, 2000 : Group Art Unit: 1614

TITLE: TREATMENT OF PULMONARY
HYPERTENSION

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 CFR 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

11/04/2004 HALI11 00000014 161445 09692807

03 FC:1806 180.00 DA

A prompt and favorable response is earnestly solicited.


Date: 11/1/04

Respectfully submitted,



A. Dean Olson
Attorney for Applicant(s)
Reg. No. 31,185

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-4904



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. PC10370A	SERIAL NO. 09/692,807
	APPLICANT Ghazwan Saleem Butrous	
	FILING DATE October 20, 2000	GROUP 1614

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	0	0	0	0	1	9	9	1/6/00	International	A61K	31/495		
	WO	9	9	2	6	9	4	6	6/3/99	International (ABSTRACT IS IN ENGLISH. A FULL TRANSLATION WILL BE PROVIDED WHEN AVAILABLE)	C07D	471/04		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Braner, D., et al., "M & B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs", <i>AJP - Heart and Circulatory Physiology</i> , Vol. 264, Issue 1, pp. H252-H258 (1993)
			Cohen, et al., "Inhibition of Cyclic 3'-5'-Guanosine Monophosphate-specific Phosphodiesterase Selectively Vasodilates the Pulmonary Circulation in Chronically Hypoxic Rats", <i>J. Clin. Invest.</i> , Vol. 97, No. 1, pp. 172-179 (1996)
			Hanasato, et al., "E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats", <i>Amer. J. of</i>

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10370A	SERIAL NO. 09/692,807
		APPLICANT Ghazwan Saleem Butrous	
		FILING DATE October 20, 2000	GROUP 1614
		Physiology, Vol. 277, No. 2, pp. L225-L232 (1999)	
		Herrmann, H., et al., "Systemic, Pulmonary, and Coronary Hemodynamics and Platelet Effects of Oral Sildenafil Citrate (Viagra) in Men with Severe Coronary Disease", <i>Circulation</i> , Vol. 100, No. 18, Suppl. 1, p. I-378, Abstract No. 1987 (1999)	
		Bigatello, L., "Strategies to Enhance the Efficacy of Nitric Oxide Therapy", <i>Respiratory Care</i> , Vol. 44, No. 3, pp. 331-339 (1999)	
		Ishikura, F., et al., "Sildenafil Citrate (Viagra) Enhances a Vasodilation by Atrial Natriuretic Peptide in Normal Dogs", <i>Circulation</i> , Vol. 110, No. 18 (Suppl. 1), p. I-177, Abstract No. 924	
EXAMINER		DATE CONSIDERED	
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

